ShannonNeville(Neville)WestinMD

Clinical Trials

• Laparoscopic Approach to Cervical Cancer Start of enrollment: 2008 Jan 01

  Completed

  Not Applicable

• Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer Start of enrollment: 2008 Nov 03

  Active, not recruiting

  Phase 2

• Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer Start of enrollment: 2010 Aug 19

  Active, not recruiting

  Phase 1

• Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Start of enrollment: 2012 Sep 01

  Completed

  Phase 1

• Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290 Start of enrollment: 2004 Aug 13

  Completed

• mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Start of enrollment: 2014 Nov 11

  Active, not recruiting

  Phase 1, Phase 2

• Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2016 Feb 04

  Active, not recruiting

  Early Phase 1

• Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer Start of enrollment: 2016 Aug 24

  Completed

  Phase 2

• Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) Start of enrollment: 2016 Jul 06

  Active, not recruiting

  Phase 1, Phase 2

• Selumetinib and Olaparib in Solid Tumors Start of enrollment: 2017 Aug 04

  Active, not recruiting

  Phase 1

• Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2019 Apr 29

  Active, not recruiting

  Phase 1

• Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Start of enrollment: 2019 Jun 07

  Active, not recruiting

  Early Phase 1

• Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer Start of enrollment: 2020 May 05

  Active, not recruiting

  Phase 3

• Prediction of Recurrence Among Low Risk Endometrial Cancer Patients Start of enrollment: 2012 Nov 08

  Recruiting

• EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors Start of enrollment: 2015 Jul 01

  Recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Start of enrollment: 2021 Dec 14

  Active, not recruiting

  Early Phase 1

  Roles: Principal Investigator, Contact

• Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2021 Oct 01

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2018 Dec 07

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer Start of enrollment: 2015 Sep 23

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer Start of enrollment: 2023 Mar 24

  Recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer Start of enrollment: 2023 Jul 12

  Recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary Start of enrollment: 2022 Dec 09

  Terminated

  Phase 1, Phase 2

  Roles: Contact

• Join now to see all